A raft of real world data for Eisai’s Fycompa has been presented at this week’s European Congress on Epileptology in Stockholm.

Data on ten Eisai-supported observational studies on clinical experience with adjunctive Fycompa (perampanel) in over 350 refractory patients across sites in the UK and Austria. The results, say Eisai, show perampanel to be generally effective and well tolerated in a variety of patient populations, including those with highly refractory epilepsy and patients with a high number of comorbidities.

In two further abstracts, metabolic parameters were assessed for the perampanel pooled Phase III global pivotal studies and an open-label extension study. Results show that blood cholesterol and triglyceride levels and glucose levels remained stable over time across a range of perampanel doses.

The most common metabolic treatment emergent adverse event reported for both studies was weight increase.  According to Christoph Baumgartner of the General Hospital Hietzing in Vienna, the new data support the use of the drug in adults and adolescents with refractory epilepsy.

Perampanel, a once-daily treatment which selectively targets AMPA receptors, is currently  indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

Speaking at a press briefing in Stockholm, Arnaud Biraben predicted that perampanel, which is generally well tolerated, would move into earlier stage treatment of epilepsy as further experience with the drug’s novel mechanism of action accumulated.